Provided by Tiger Trade Technology Pte. Ltd.

RAPT Therapeutics, Inc.

34.04
+0.86002.59%
Post-market: 34.340.3000+0.88%18:17 EST
Volume:369.55K
Turnover:12.56M
Market Cap:943.28M
PE:-5.16
High:35.35
Open:35.18
Low:33.18
Close:33.18
52wk High:42.39
52wk Low:5.67
Shares:27.71M
Float Shares:13.26M
Volume Ratio:1.01
T/O Rate:2.79%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-6.5969
EPS(LYR):-25.4880
ROE:-85.37%
ROA:-51.35%
PB:6.21
PE(LYR):-1.34

Loading ...

TD Cowen Initiates Coverage on RAPT Therapeutics With Buy Rating

MT Newswires Live
·
Yesterday

RAPT Therapeutics Chief Medical Officer William Ho to Depart at Year-End

Reuters
·
Nov 29

J.P. Morgan Remains a Buy on RAPT Therapeutics (RAPT)

TIPRANKS
·
Nov 12

Rapt Therapeutics Unveils Pipeline Progress for Ozureprubart in Allergic Diseases

Reuters
·
Nov 11

RAPT Therapeutics Inc expected to post a loss of 88 cents a share - Earnings Preview

Reuters
·
Nov 07

RAPT Therapeutics : Barclays Cuts Target Price to $56 From $58

THOMSON REUTERS
·
Nov 07

Rapt Therapeutics shares ‘exceptionally compelling,’ says Clear Street

TIPRANKS
·
Nov 07

Promising Clinical and Financial Developments Drive Buy Rating for RAPT Therapeutics

TIPRANKS
·
Nov 07

Buy Rating for RAPT Therapeutics Driven by Promising Ozureprubart Data and Strategic Growth Plans

TIPRANKS
·
Nov 07

RAPT Therapeutics Q3 EPS $(0.65) Beats $(0.80) Estimate

Benzinga
·
Nov 06

Rpt- RAPT Therapeutics Q3 EPS USD -0.65

THOMSON REUTERS
·
Nov 06

Rapt Therapeutics Q3 net loss narrows as R&D costs drop

Reuters
·
Nov 06

RAPT Therapeutics, Inc. : H.c. Wainwright Raises Target Price to $72 From $27

THOMSON REUTERS
·
Oct 27

Clear Street positive on Rapt Therapeutics into food allergy study

TIPRANKS
·
Oct 27

Guggenheim Initiates RAPT Therapeutics at Buy With $70 Price Target

MT Newswires Live
·
Oct 27

RAPT Therapeutics Initiates Prestige Phase 2B Clinical Trial of Ozureprubart (Rpt904) in Patients With Food Allergies

THOMSON REUTERS
·
Oct 27

RAPT Therapeutics Initiates prestIgE Phase 2b Clinical Trial of Ozureprubart (RPT904) in Patients with Food Allergies

GlobeNewswire
·
Oct 27

LifeSci Capital Remains a Buy on RAPT Therapeutics (RAPT)

TIPRANKS
·
Oct 25

Leerink Partners Keeps Their Buy Rating on RAPT Therapeutics (RAPT)

TIPRANKS
·
Oct 22

BRIEF-RAPT Therapeutics Announces Pricing Of Public Offering Of 8.3 Million Shares At $30.00 Each

Reuters
·
Oct 22